DexCom Growth Opportunities in the U.S. Market Q1 2026

DexCom (DXCM) growth opportunities for U.S. market penetration as of Q1 2026

As of DexCom’s Q1 2026 earnings call, management views U.S. CGM penetration as the central penetration opportunity: only ~30% of “covered lives” are using CGM, meaning ~two-thirds of covered patients are not yet using it. ¹ The company’s growth plan in the U.S. emphasizes (1) expanding payer coverage, (2) expanding the product “addressable base” within diabetes categories (especially type 2 non-insulin), and (3) improving onboarding, awareness, and conversion from “covered” to “active users.” ¹²³

---

1) Penetration gap in “covered lives” (primary U.S. runway)

• DexCom says the U.S. CGM category has ~30% penetration into covered lives, implying only 1 in 3 covered people uses CGM, leaving the other 2/3 out of the CGM ecosystem (before considering future coverage expansion). ¹
• Management links U.S. growth to both new patient starts and the ability to improve retention and utilization as coverage expands and patients adopt DexCom products/services. ⁴¹

What this means for penetration: even without additional payer coverage, DexCom believes there is room to convert covered patients into active CGM users. ¹

---

2) Commercial coverage expansion in type 2 non-insulin (large, incremental addressable population)

DexCom highlights type 2 non-insulin as the most important U.S. penetration pocket because it combines (a) a growing clinical/payer awareness story and (b) large population counts.

• DexCom attributes meaningful U.S. first-quarter momentum to type 2 diabetes, stating that expanded reach and product momentum led to strong Q1 share gains, with the largest increase coming from people with type 2 diabetes not on insulin. ²
• DexCom frames coverage growth around a “coverage unlock” pipeline and cites growing clinical awareness plus payer recognition of outcomes. ²

Named payer expansion catalyst (U.S. commercial):

• DexCom announces a reimbursement win with Prime Therapeutics (commercial space), stating that as of this summer Prime will begin covering DexCom CGM for all people with diabetes, and that this puts DexCom on track for commercial coverage for more than 7 million type 2 non-insulin lives by the end of this year. ²

Penetration impact mechanism: more covered lives directly increases the pool of patients who can transition from non-use to use, and DexCom also claims it is improving its ability to target these new covered groups, citing share gains in that covered group. ¹

---

3) G7 15-day rollout to drive adoption within existing users and attract new customers

Beyond payer coverage, DexCom’s penetration plan depends on products that reduce friction (wear time, perceived accuracy, survivability) and increase the value proposition to both patients and prescribers.

• DexCom expanded the launch of the DexCom G7 15-day system across all channels in the U.S. during Q1 2026. ⁵
• Management says the rollout has been well received, and points specifically to a new sensor algorithm delivering its highest accuracy level to date, and to improvements that can attract new customers. ⁵
• DexCom also expects existing users to shift to the 15-day product to experience longer wear time and improved performance. ⁵

Penetration impact mechanism: longer-wear and higher-perceived accuracy can improve conversion from “aware/covered” to “adopting and switching,” and reduce churn risk by strengthening satisfaction. ⁵³

---

4) Coverage unlocking through additional payer/plan pathways (commercial “and then” Medicare/CMS)

DexCom’s growth thesis is that coverage expansion is the driver of durable U.S. growth—commercial first, and then Medicare/CMS for the remaining majority of non-users within type 2 non-insulin.

• Management says it will not be satisfied until there is coverage for all people with diabetes. ⁶
• It identifies the largest single driver toward that goal as CMS coverage for type 2 non-insulin, noting that around half of type 2 diabetes patients not using insulin are in the Medicare population. ⁶
• On timing, DexCom’s CFO says it is hard to estimate exactly when CMS coverage will come, but it is a “matter of time.” ⁷
• DexCom also indicates CMS requirements could likely differ in form (e.g., documentation or evidence like diagnosis/therapy), but management does not expect any such requirement to materially limit its ability to impact the population. ⁸

Penetration impact mechanism: Medicare coverage would unlock a very large covered-lives pool for CGM in the type 2 non-insulin segment, which DexCom calls a potential source of durable growth for a long time in the U.S. ⁴

---

5) Evidence and trial readouts to accelerate payer and clinician adoption (especially for type 2 non-insulin)

Penetration depends not only on coverage decisions but also on clinician/patient confidence to prescribe and use CGM.

• DexCom says it sees upgraded clinical guidance (ADA Standards of Care) recommending CGM use for all people with diabetes and cites expanding real-world evidence. ⁶
• As an example, DexCom cites its 12-month type 2 non-insulin registry data presented at ATTD, stating CGM delivered a statistically significant A1c reduction over one year in a broad population with strong utilization. ⁶
• DexCom says it is completing a randomized control trial (RCT) for type 2 non-insulin and frames the ADA readout as potentially pivotal for payer evidence. ⁶
• Management states it expects the ADA trial readout to show “really significant improvements,” and that the ADA readout will be the first time they conduct a full readout (and that they are not planning to publish before ADA). ⁴

Penetration impact mechanism: stronger clinical evidence can reduce barriers for coverage expansion and increase clinician willingness to write prescriptions, supporting conversion from coverage → utilization. ⁶⁴

---

6) Commercial execution: education, prescription flow, and conversion to active users

DexCom emphasizes operational and sales execution to overcome adoption friction, especially when “covered” does not automatically mean “using.”

• DexCom states the key issue for broad adoption is educating around the coverage that exists, noting that when only about 25% of the type 2 non-insulin population is covered today, it can be complicated for primary care physicians who are not prescribing CGM daily. ³
• It says it is targeting physicians and prescribers using advanced tools, and notes primary care is the main place these patients are seen; accordingly, DexCom expanded its salesforce in 2024 to call on a broader group of primary care physicians. ³

Penetration impact mechanism: improving prescriber awareness and prescription-writing workflows supports market penetration even as coverage expands from 25% toward higher levels. ³

---

Bottom line (U.S. penetration opportunities by Q1 2026)

As of Q1 2026, DexCom’s primary U.S. market penetration opportunities are:

1. Convert the penetration gap: with ~30% CGM penetration into covered lives, DexCom sees a large “covered but not using” base. ¹
2. Unlock major commercial type 2 non-insulin coverage: Prime Therapeutics coverage starting in summer is expected to drive commercial coverage for >7 million type 2 non-insulin lives by year-end. ²
3. Increase adoption and switching with G7 15-day: U.S. channel expansion of 15-day plus algorithm/accuracy improvements is designed to attract new customers and help existing users transition. ⁵
4. Prepare for Medicare/CMS coverage: DexCom views CMS coverage for type 2 non-insulin as the largest remaining penetration unlock, though timing is uncertain but “a matter of time.” ⁶⁷
5. Strengthen evidence to accelerate adoption: registry outcomes and an RCT readout planned for ADA 2026 are intended to underpin payer/clinical confidence and long-term coverage growth. ⁶⁴
6. Improve conversion from coverage to active use through education and prescriber workflow support, especially in primary care. ³

These opportunities are positioned to reinforce one another: coverage expansion enlarges the covered population, product upgrades improve perceived value and adoption, and clinical evidence plus education supports faster conversion to active CGM use. ¹²⁵³⁶